Profile

Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation. Its patented GMP process produces natural vesicles enriched with anti-inflammatory and anti-fibrotic cargo. Supported by strong preclinical efficacy in large-animal models, it is advancing toward regulatory submission for a Phase 1 trial in 2026. Its technology addresses a major unmet need, offering safer, targeted prevention of post-operative atrial fibrillation with potential expansion into broader arrhythmia and cardiovascular indications.

Rhythm Biotherapeutics Inc. Logo
rthm.bio

Contact

Event details

Date: January 12 - 14, 2026

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total
  • 20/20 OptimEyes Technologies Inc.
    20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
  • BioBox
    BioBox is a data integration and decision-intelligence platform for drug discovery. It helps biopharma bring…
  • Eurofins CDMO Alphora Inc.
    Eurofins CDMO Alphora develops and…
  • Fibra
    Fibra turns everyday underwear into a real-time reproductive health platform — capturing critical biomarker data…
  • GL Chemtec International Ltd.
    For over two decades, Toronto area-based GL CHEMTEC has been dedicated to delivering innovative…
  • HDAX Therapeutics
    HDAX Therapeutics, a biotechnology company pioneering a novel approach to target…
  • ImmunoBiochem Corporation
    ImmunoBiochem is a pharma-partnered biotech developing novel bioconjugate therapeutics, such as…
  • Iseehear Inc.
    Iseehear Inc. is a leading provider of comprehensive IT solutions for…
  • Kapoose Creek Bio
    Kapoose Creek Bio is pioneering a new generation of therapeutics by fusing nature’s untapped chemistry with…
  • Lumerate
    Lumerate is launching a new software brand called BioBackers - the intelligence platform for life science…
  • Medicenna Therapeutics
    Medicenna is a clinical-stage immunotherapy company pioneering best- and/or first-in-class Superkines -…
  • Noa Therapeutics
    Noa Therapeutics has developed a proprietary NRF2-…
  • Nucro-Technics
    Nucro-Technics is a GLP- and…
  • Paradox Immunotherapeutics
    Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating…
  • Pattern Pharma Inc.
    Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. PQ…
  • QurCan Therapeutics Inc.
    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS…
  • Rhythm Biotherapeutics Inc.
    Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation…
  • Spiderwort Biotechnologies Inc.
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • Tenomix
    Tenomix’s mission is to develop novel technologies that target inefficiencies in the pathology workflow, optimize…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…